Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1643 1645
This examiner grants 44% of resolved cases
Alana Harris Dent serves in Tech Center 1600 and Art Unit 1600, where they have resolved 747 cases. The examiner has an allowance rate of 44.2 percent, which indicates a challenging environment for applicants. The median days to allowance is 1359, representing the typical timeframe for the 747 cases that have reached a grant.
The interview lift of 32.0 percent is a significant factor, suggesting that interviews are a highly effective tool for this examiner. This 32.0 percent lift means that cases with an interview have a much better chance of success than the base rate would indicate. Practitioners should prioritize direct communication to overcome the hurdles present in this unit.
With 747 resolved cases, Dent's data highlights a clear strategy. The 44.2 percent allowance rate and 32.0 percent interview lift together point toward the necessity of verbal advocacy. The 1359-day median to allowance provides a timeframe for prosecution that applicants must manage alongside these statistical trends.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18359562 | INTERNALIZING RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS | Non-Final OA | The Regents of the University of California |
| 18247144 | INTEGRATED PROTEOMIC BIOMARKERS FOR THE DETECTION OF AGGRESSIVE PROSTATE CANCER | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18041059 | COMPANION DIAGNOSTIC FOR RTK INHIBITORS | Non-Final OA | The Regents of The University of Michigan |
| 18041527 | sBCMA Variants and FC Fusion Proteins Thereof | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17916942 | VACCINE PLATFORM FOR THE INDUCTION OF SYSTEMIC IMMUNE RESPONSES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17920860 | METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, A CHEMORADIATION THERAPY AND A PARP INHIBITOR | Non-Final OA | Merck Sharp & Dohme LLC |
| 17423602 | A METHOD FOR TREATING CANCER WITH IMMUNOGLOBULIN E (IGE) | Final Rejection | KING'S COLLEGE LONDON |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 17101028 | METHODS AND ASSAYS RELATING TO CIRCULATING TUMOR CELLS | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 16640942 | METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES | Final Rejection | The General Hospital Corporation |
| 18005802 | Multiple Myeloma Mapping and Uses Thereof | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18309985 | TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA | Final Rejection | Roche Diagnostics Operations, Inc. |
| 18264340 | EXTRACELLULAR VESICLE DRUG ANALYSIS FOR REAL-TIME MONITORING OF TARGETED THERAPY | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 17416227 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17954477 | PHARMACEUTICAL COMPOSITION | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 16088727 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCERS | Non-Final OA | TORAY INDUSTRIES, INC. |
| 17630050 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 17630046 | DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF C5-RELATED DISEASES BY THE USE OF THE ANTI-C5 ANTIBODY CROVALIMAB | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 18299415 | METHOD OF TREATING CANCER WITH A BRCA1-ASSOCIATED PROTEIN 1 INHIBITOR AND A DEATH RECEPTOR LIGAND | Final Rejection | UCL Business PLC |
| 18046300 | PD-1 SIGNAL INHIBITOR COMBINATION THERAPY | Non-Final OA | KYOTO UNIVERSITY |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | Final Rejection | Evaxion Biotech A/S |
| 18312719 | SYSTEMS AND METHODS FOR PROMOTING REMYELINATION WITH FACTORS DERIVED FROM UMBILICAL CORD BLOOD MACROPHAGES | Final Rejection | Duke University |
| 17626315 | ENGINEERING NOTCH LIGANDS TO ENHANCE THE ANTI-TUMOR ACTIVITY OF ADOPTIVELY TRANSFERRED T CELLS | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18460226 | METHODS OF ASSESSING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATION AND OF IDENTIFYING AND TREATING PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION | Non-Final OA | Corcept Therapeutics Incorporated |
| 17803392 | Fusion Protein Composition(S) Comprising Masked Type I Interferons (IFNa and IFNß) For Use in the Treatment of Cancer and Methods Thereof | Non-Final OA | Nammi Therapeutics, Inc. |
| 17638144 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING ANTICANCER VIRUS, IMMUNE CHECKPOINT INHIBITOR AND HYDROXYUREA AS ACTIVE INGREDIENTS | Non-Final OA | Bionoxx Inc. |
| 18356417 | GENETIC VARIATIONS ASSOCIATED WITH BENIGN PAROXYSMAL POSITIONAL VERTIGO | Non-Final OA | Father Flanagan's Boys' Home Doing Business as Boys Town National Research Hospital |
| 18073935 | CYTOKINE CONJUGATES | Final Rejection | AMUNIX PHARMACEUTICALS, INC. |
| 17419634 | ANTICANCER COMPOSITIONS COMPRISING IMMUNE CHECKPOINT INHIBITORS | Final Rejection | NOAHM INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy